drugset / Trial / NCT01765829

Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis

NCT01765829

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to assess if patients who continue with antipsychotic treatment for 12 or more months show the same risk of relapse (measured by PANSS) that patients with the same medical condition who have followed a discontinuation treatment scheme based in the presence of prodromes. The candidates should accomplish the following criteria: first episode of non-affective psychosis who have followed antipsychotic treatment for 12 months and who have already shown remission criteria.

Timeline

Start
2012-11
Primary completion
2015-11
Completion
2015-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Amisulpride Small molecule
Subject Aripiprazole Other / unclassified
Subject Asenapine Other / unclassified
Subject CLOTHIAPINE Small molecule
Subject Chlorpromazine Small molecule
Subject Clozapine Other / unclassified
Subject Droperidol Small molecule
Subject Flupentixol Unknown
Subject Haloperidol Other / unclassified
Subject Levomepromazine Small molecule
Subject Olanzapine Small molecule
Subject Paliperidone Unknown
Subject Periciazine Small molecule
Subject Pimozide Small molecule
Subject Pipotiazine palmitate Small molecule
Subject Quetiapine Small molecule
Subject Risperidone Other / unclassified
Subject Sertindole Small molecule
Subject Sulpiride Small molecule
Subject Tiapride Small molecule
Subject Trifluoperazine Small molecule
Subject Ziprasidone Small molecule
Subject Zuclopenthixol Unknown

Indications